Treace Medical Concepts, Inc. (TMCI)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$4.81-1.43%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · TMCI
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue efforts to reduce cash usage by about half in 2026 compared to 2025 through operational discipline and expense management.
Stated as a priority in 3 of last 3 quarters. Year-to-date cash usage was reduced by 57% or $3.6 million through 2026-Q2 compared to the same period in 2025. Management has consistently reiterated the goal of approximately 50% cash usage reduction for full-year 2026, and the trajectory is delivering against this target.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“The Company reiterates its expectation for a reduction in cash usage of approximately 50% for full-year 2026 as compared to the full year 2025.”
“The Company reiterates its expectation for a reduction in cash usage of approximately 50% for full-year 2026 as compared to the full year 2025.”
“The Company expects a reduction in cash used of 43% to 47% for full-year 2025 as compared to full-year 2024.”
Sustain full-year 2026 revenue guidance in the range of $202 million to $212 million, reflecting stable to slightly declining revenue compared to 2025.
Stated as a priority in 3 of last 3 quarters. Revenue declined from $100.0 million in first half 2025 to $92.6 million in first half 2026. Management has maintained full-year 2026 revenue guidance in the range of $202 million to $212 million, reflecting a decline of up to 4% compared to 2025. The trajectory shows stable to slightly declining revenue consistent with guidance.
“The Company is raising its full-year 2026 revenue guidance to be in the range of $204 million to $212 million.”
“The Company is reaffirming its full-year 2026 revenue guidance to be in the range of $202 million to $212 million.”
“The Company is updating its full-year 2026 revenue guidance to $202 million to $212 million.”
Increase surgeon adoption of new bunion correction systems and expand market share through product launches and portfolio utilization.
Stated as a priority in 2 of last 2 quarters. Surgeon adoption of the expanded bunion portfolio increased from 35% in 2026-Q1 to approximately 40% in 2026-Q2. Management emphasizes continued focus on commercial execution and new product launches to drive market share growth. The trajectory shows progress in surgeon adoption consistent with stated priorities.
“Increased adoption of expanded bunion portfolio with approximately 40% of Lapiplasty surgeon users incorporating new bunion systems.”
“We remain focused on driving surgeon adoption of our broadened portfolio and commercializing our 2026 new product launches.”
Over the trailing year it converted -0.08x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
8 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.